WFSBP 2019 Final Program

32 Scientific Program / Tuesday, 4 June 2019 WFSBP 2019 TUE T14: DRUG DEVELOPMENT S-25 SYMPOSIUM 08:15–09:45 East Meeting Room 16 Targeting the alpha-2C adrenoreceptor in psychiatry: Reasons for excitement Chair: Brian Harvey, South Africa Co-Chair: Torgny Svensson, Sweden 001 How successful have we been in targeting alpha-2-adrenoceptors in the treatment of major neu- ropsychiatric disorders?: An overview and road-map to improve outcomes Torgny Svensson, Sweden 002 Selective alpha-2C antagonists have important psy- chopharmacological qualities: Experience from pre-clin- ical research in translational animal models Brian Harvey, South Africa 003 Industry perspective on the progress, application and relevance of developing selective alpha-2C antago- nists for neuropsychiatric disorders Mohammed Shahid, Finland T1: ADDICTIVE DISORDERS S-26 SYMPOSIUM 08:15–09:45 East Meeting Room 9 Recent advances in Cannabis Use Disorders Chair: E. Mohandas, India Co-Chair: Firoz Kazhungil, United Arab Emirates 001 Neurobiology of Cannabis induced psychosis Narayan Mutalik, India 002 Cannabis, synthetic Cannabinoids and executive dysfunction Rajan Nishanth Jayarajan, Australia V. Kasal 003 Evidence based pharmacotherapies in Cannabis dependence Firoz Kazhungil, United Arab Emirates 004 Medical Cannabis: Pros & Cons Shubratha Sridhara Kalmane, India G. Rakesh T45: PSYCHOGERIATRICS WS-04 WORKSHOP 08:15–09:45 East Meeting Room 7 Bridging knowledge and practice in cross-cultural mental health research Chair: Wah-Yun Low, Malaysia Co-Chair: Saroja Krishnaswamy, Australia 001 Malaysian Mental Health Survey (MMHS) and the current situation Kavitha Subramaniam, Malaysia 002 Implementation challenges to mental health inter- vention Wen-Ting Tong, Malaysia 003 Screening of mild cognitive impairment and its related psycho-social aspects among older persons in primary care clinics: A case study Alexander Lourdes Samy, Malaysia 004 Translating mental health evidence into policy: Issues and challenges Noor Ani Ahmad, Malaysia FC-02 FREE COMMUNICATION SESSION 08:15–09:45 East Meeting Room 11 Schizophrenia Chair: Frederico Garcia, Brazil 001 Antipsychotics in adolescents at Ultra-High Risk of psychosis: findings from an Italian 1-year longitudinal study Lorenzo Pelizza, Italy S. Azzali, F. Paterlini, S. Garlassi, I. Scazza, L. R. Chiri, M. Poletti, S. Pupo, A. Raballo 002 Increased number of ribosomal genes: A possible genetic reason for ahort lifespan of SZ patients Natalia Zakharova, Russia A. Y. Morozova, G. P. Kostyuk, A. V. Martynov, E. S. Ershova, V. A. Sergeeva, N. S. Ter-Kasparyants, A. M. Reznik, V. G. Golimbet, N. N. Veiko, S. V. Kostyuk 004 Add-on ramelteon therapy in patients with pre- dominantly negative symptoms in schizophrenia: An open label randomized controlled trial Archana R. Maiti, B. R. Mishra, M. Jena, S. Nath 005 Who benefits from interventions to improve cognition among people with schizophrenia at clinical settings? Alexander John, Australia M. Dragovic, K. Yeak